课题基金 / 基金详情

Pre-clinical drug study to assess recurrence of HER2+ breast cancer

Pre-clinical drug study to assess recurrence of HER2+ breast cancer
评估 HER2 乳腺癌复发的临床前药物研究
批准号：
349829
负责人：
Lanoue Danielle
金额：
$1.27万
依托单位：
Dalhousie University (Nova Scotia)
依托单位国家：
加拿大
项目类别：
Studentship Programs
财政年份：
2015
资助国家：
加拿大
项目状态：
已结题
起止时间：
2015-12-01 至 2016-12-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=349829&lang=en
关键词：
Autophagy Breast Cancer Cell Metabolism Her2 Lkb1 Pro-Survival Recurrence Signalling Tumour Suppressor

项目摘要

项目成果

Lanoue Danielle的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Breast cancer is the second leading cause of death amongst Canadian women. Despite advances in early detection, diagnosis and treatment, a proportion of women diagnosed with breast cancer do not survive. It is likely that many of these deaths are attribut
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Concurrent loss of tumour suppressors LKB1 and BRG1 contribute to epigenetic dysregulation in lung tumourigenesis
海外基金